Home Blog Page 946

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

HAMILTON, ON, Feb. 24, 2026 /PRNewswire/ — AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics’ First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart (RV‑01) by providing GMP manufacturing and distribution services for the radiotherapeutic drug product, after successfully developing and qualifying the radiolabeling process and analytical methods using a phase-appropriate approach that expedited IND filing.

AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics’ Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)

The Phase 1/2a clinical study is designed as a dose-escalation and expansion trial evaluating the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu‑BetaBart, while also determining the recommended dose for future studies. 177Lu-BetaBart (RV‑01) is a 177Lutetium‑conjugated monoclonal antibody engineered to target the 4Ig isoform of B7‑H3, an immune checkpoint molecule overexpressed across multiple solid tumor types.

“Enabling the first patient dose of 177Lu-BetaBart reflects what matters most to us, ensuring that high‑quality radiopharmaceuticals are manufactured, released, and delivered on time so patients can access innovative therapies without delay,” said Bruno Paquin, Chief Executive Officer of AtomVie. “Our team is deeply focused on operational excellence and reliability, supporting our partners from early clinical development through global supply.”

“Dosing the first patient in the Phase 1/2a clinical study of 177Lu‑BetaBart represents an important milestone for Radiopharm Theranostics,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “We appreciate AtomVie’s manufacturing expertise and commitment to quality as we advance BetaBart for patients with aggressive and difficult‑to‑treat solid tumors.”

About BetaBart (RV-01)

RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and The University of Texas MD Anderson Cancer Center. 177Lu-BetaBart is a 177Lutetium-conjugated therapeutic that targets B7-H3, an immune checkpoint molecule that is overexpressed in several tumor types. Multiple preclinical studies with BetaBart have shown tumor shrinkage and prolonged survival in animals treated with the radiotherapeutic agent.

About the Phase 1/2a Clinical Trial

The FIH Phase 1/2a study (NCT07189871) is designed to establish the safety profile, biodistribution, pharmacokinetics, and radiation dosimetry of 177Lu-Betabart . The study aims to enroll 61 eligible participants who have a documented history of histopathologically confirmed castrate resistant prostate cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, head and neck squamous cell cancer, ovarian cancer, cervical cancer, endometrial cancer, triple negative breast cancer, or esophageal squamous cell carcinoma.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm Theranostics is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

For more information, please contact:
Riccardo Canevari, CEO & Managing Director
Phone number: +1 862 309 0293
e-mail id: rc@radiopharmtheranostics.com

About AtomVie(AtomVie)

AtomVie is a global leading CDMO for the GMP manufacturing and worldwide distribution of clinical and commercial radiopharmaceuticals. AtomVie offers the full range of scientific, technical, regulatory, quality and logistics services combined with a specialized infrastructure for the development of radiopharmaceuticals from clinical studies, phases I to III, to commercial markets. AtomVie currently serves international clients conducting clinical studies in over 28 countries worldwide. AtomVie is currently building and commissioning a new state-of-art, purpose-built 72,300 sq ft facility, set for operational readiness in H2 2026. For additional details visit our website https://www.atomvie.com/

For more information, please contact:
Tina Chainani, Business Development Manager
Phone number: +1 437 239 1288
e-mail id: tina.chainani@atomvie.com

3iQ Announces Earlier Than Anticipated Closing of Previously Disclosed Transaction with Coincheck Group N.V.

TORONTO, Feb. 24, 2026 /PRNewswire/ — 3iQ Corp. (“3iQ”), a global pioneer in institutional digital asset investment solutions, is pleased to announce that the acquisition involving Coincheck Group N.V. (see press release from January 8, 2026 here) is now expected to close on or about February 28, 2026, notwithstanding the previously anticipated closing date of on or about April 1, 2026. 

Following 3iQ’s subsequent Notice to Unitholders issued on February 2, 2026 (the “Notice”), pursuant to the previously disclosed transaction (the “Proposed Transaction”), Coincheck Group N.V. (“the Purchaser”) will indirectly acquire all of the issued and outstanding Class A Common Shares and certain Class B Common Shares of 3iQ Digital Holdings Inc., 3iQ’s parent company (the “Parent”) from the Purchaser’s majority shareholder, Monex Group Inc., collectively representing approximately 96.77% of the issued and outstanding shares of the Parent and approximately 97.77% of the votes attaching to shares of the Parent, and may additionally directly acquire the remaining Class B Common Shares of the Parent, representing 3.23% of the issued and outstanding shares of the Parent and approximately 2.23% of the votes attaching to shares of the Parent from the remaining minority shareholders.

As previously communicated to unitholders of 3iQ in the Notice, following the completion of the Proposed Transaction, 3iQ will continue to be a wholly-owned subsidiary of the Parent, as the Parent controls the Purchaser. Consequently, the ultimate beneficial majority ownership of 3iQ is not changing, as Monex Group, Inc. owns more than 80% of the issued and outstanding shares of the Purchaser.  Additionally, the accelerated timing of the closing does not result in any immediate plans to change the investment objectives of 3iQ’s funds, increase the management fees or operating expenses paid by 3iQ’s funds, change service providers or change the role of 3iQ.

The accelerated closing does not require any action by the unitholders of 3iQ funds. 3iQ remains committed to maintaining continuity of operations and compliance with applicable securities laws.

About 3iQ Digital Asset Management

Founded in 2012, 3iQ is one of the world’s leading alternative digital asset managers, pioneering institutional-grade investments. 3iQ launched the world’s first Digital Assets Managed Account Platform (QMAP), a hedge fund investment solution, offering innovative risk-managed investment solutions to gain exposure to digital assets. 3iQ was also the first to launch a Bitcoin and Ethereum ETP listed on a major global stock exchange, integrate staking into its Ethereum and Solana ETPs boosting investor returns, and offering other regulated ETPs. In 2024, Monex Group, a leading Japanese financial group, took a majority stake in 3iQ. Since 2012, 3iQ has been at the forefront of innovation in digital asset investment management. To learn more about 3iQ, visit 3iq.io.

W: https://www.3iq.io/
L: https://www.linkedin.com/company/3iq-corp/
X: https://x.com/3iq_corp

Media Contacts for 3iQ

Europe
Angus Campbell
Nominis Advisory
angus@nominis.co

North America
Ryan Graham
JConnelly
+1 862-777-4274
rgraham@jconnelly.com

Julie Mercuro
JConnelly
+1 973-349-6471
jmercuro@jconnelly.com

 

Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group’s Yanghe Investment Joins as a Strategic Shareholder

SHANGHAI, Feb. 24, 2026 /PRNewswire/ — Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (“Sanyou Bio”), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Haier Financial Holdings have been formally acquired by existing shareholder Shanghai Liferiver Biotechnology Co., Ltd. (“Liferiver Biotech”) and new strategic investor Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd. (“Yanghe Investment”).

The restructuring is designed to optimize corporate governance and strengthen industrial synergies. As a long-standing strategic partner of Sanyou Bio, Liferiver Biotech’s decision to increase its stake reflects strong confidence in Sanyou Bio’s core technology capabilities and growth trajectory. Since their initial partnership, the two companies have achieved deep collaboration across innovative biologics automation, COVID-19 therapeutic antibody development, and other key areas. With the increased shareholding, both parties plan to intensify their joint efforts in novel biologics R&D, accelerate development timelines, and enhance overall competitiveness.

At the same time, the introduction of Yanghe Investment as a new strategic shareholder will bring additional industry resources and growth momentum to Sanyou Bio. Yanghe Investment, headquartered in the Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone, is a dedicated investment platform under Zhuhai Gree Group and is registered with the Asset Management Association of China for private fund management. The firm was jointly established by leading healthcare companies, including Improve Medical, Hokai Medical, Shandong JW Medical, and David Medical. Yanghe Investment focuses on growth- and expansion-stage investments in biopharmaceuticals, medical services, and health products. As of October 2025, Yanghe Investment has invested in 17 companies and holds controlling stakes in 20 entities, with representative investments including Dayu Tianxia, Guangzhou Ruitong Biotech, Beijing Linkedcare Medical, Vishee Medical, and Micomme Medical.

Dr. Lang Guojun, Founder and CEO of Sanyou Bio, said: “We are deeply grateful to Liferiver Biotech for their continued trust and partnership. This increased investment is a renewed endorsement of our team and business model. We also warmly welcome Yanghe Investment. Their deep expertise in healthcare and extensive industry network will be instrumental as we enter our next phase of growth. Looking ahead, Sanyou Bio will continue to leverage our AI-powered Super-Trillion Antibody Libraries (AI-STAL) to build a world-leading Innovation Hub For Original Drug Discovery, accelerating global drug discovery in collaboration with all our partners.”

Dr. Shao Junbin, Chairman and General Manager of Liferiver Biotech, stated: “As a long-term partner and core shareholder, we remain highly confident in Sanyou Bio’s potential. We will continue to provide full support, financially, technologically, and commercially, to deepen our collaboration in automated biologics R&D and technology translation. Together, we are building a new digital-intelligence paradigm for drug discovery and accelerating the journey from lab bench to clinic.”

Li Xiaoming, General Manager of Yanghe Investment, commented: “Sanyou Bio possesses deep technical expertise and a clear strategic vision in innovative drug discovery, which aligns closely with our investment thesis. Following this strategic investment, we will leverage our shareholder resources and industry investment capabilities to create synergies, support the expansion of Sanyou Bio’s R&D operations, and drive mutual value creation.”

Sanyou Biopharma is a biopharmaceutical high-tech company focused on early-stage R&D services for innovative biologics. In recent years, the Company has continued to deepen its capabilities in AI-integrated Super-Trillion Antibody Libraries (AI-STAL), entering a new dual-engine phase driven by both. Building on this foundation, Sanyou Biopharma has proposed an ecosystem vision to build a world-leading Innovation Hub For Original Drug Discovery. Commercially, its network covers China, North America, and Europe. The Company has served nearly 2,000 customers worldwide, delivered more than 2,000 projects, and signed over 60 collaborations—among which 10 have completed IND filings, 8 are active clinical programs, and 3 have advanced to Phase III or pivotal/confirmatory clinical stages.

This strategic shareholding restructuring not only optimizes Sanyou Biopharma’s ownership structure but also delivers the dual benefits of continued support from existing shareholders and strong empowerment from a new strategic investor—further consolidating high-quality resources across the biopharmaceutical industry. With coordinated support from all shareholders, Sanyou Biopharma will continue to strengthen its core competitiveness and accelerate the build-out of its innovation foundry, injecting new momentum into biopharma innovation.

About Sanyou

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology, with the mission of “making innovative biologics R&D easy for clients worldwide”.

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models.

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages.

The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

Frost & Sullivan: SharpenCX Receives the 2026 North American Cloud Contact Center Customer Value Leadership Recognition for Excellence in Trust-Driven CX Innovation

Frost & Sullivan recognizes SharpenCX for delivering customer trust, transparency, and reliability through a cloud-native architecture and AI-driven workflows.

SAN ANTONIO, Feb. 24, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that SharpenCX has been named the 2026 North American Customer Value Leadership Recognition in the cloud contact center sector for its outstanding achievements in financial strength, strategic expansion, operational efficiency, and customer-centered execution. This recognition highlights SharpenCX’s consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. SharpenCX excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale. Guided by a long-term growth strategy focused on customer acquisition, customer service experience, customer confidence, and brand equity, SharpenCX has shown its ability to adapt and lead in a rapidly evolving cloud communications landscape. The company’s strategic agility and sustained investment in architectural simplicity, operational optimization, and market-relevant growth have enabled it to scale effectively across North America while maintaining financial discipline and transparency.

Innovation remains central to SharpenCX’s approach. Its cloud-native contact center platform empowers agents through streamlined omnichannel workflows, modular adoption frameworks, and AI-driven automation that enhance performance while reducing technical friction. Supported by a rapidly maturing partner ecosystem, SharpenCX delivers adaptable solutions that allow organizations to evolve workflows and integrate new capabilities without the complexity or downtime common among legacy platforms. “Sharpen operates from a unified, cloud-native architecture that reduces technical friction and supports efficient internal execution. By maintaining a single, coherent system rather than a patchwork of acquired solutions, the company accelerates development cycles, reduces rework, and focuses resources on innovation rather than maintaining legacy complexity,” said Sebastian Menutti, Industry Director, ICT at Frost & Sullivan.

SharpenCX’s unwavering commitment to customer experience strengthens its position in the market. Through a lifecycle engagement model built on continuity and accountability, the company provides stable guidance from onboarding through ongoing optimization. Transparent pricing structures, leadership accessibility, and low-friction platform adaptability reinforce long-term customer trust while delivering measurable total cost of ownership savings. “We built Sharpen on one cloud-native foundation, so everything works together,” said Tom Fisher, president of SharpenCX. “We added even more value by making it flexible enough that customers can adopt it as needed, rather than forcing them to rip and replace. They get coherence underneath and choice on top — and we’re proud Frost & Sullivan recognized the benefits of our strategy.”

Frost & Sullivan commends SharpenCX for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of the cloud contact center industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the Customer Value Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. It recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact

Camila Tinajero
E: camila.tinajero@frost.com 

About SharpenCX

SharpenCX is a cloud-native contact center platform designed to reduce complexity and improve performance. Its modular framework allows organizations to adopt capabilities such as AI-powered workflows and outbound engagement incrementally, without disruptive migrations.

Headquartered in Indianapolis, Indiana, Sharpen serves mid-market and regulated industries including healthcare, financial services, and insurance. With transparent subscription pricing and a 95% customer retention rate, Sharpen focuses on delivering measurable, long-term customer value.

Contact

Melissa Schmitz
E: mschmitz@sharpencx.com

From Singapore Success to North American Solutions: Legend Robot Unveils First-of-its-Kind Mobile Spraying Fleet at CONEXPO

LAS VEGAS, Feb. 24, 2026 /PRNewswire/ — Amidst a critical skilled labor shortage and rising construction costs in North America, Legend Robot makes its regional debut at CONEXPO-CON/AGG (Booth N12934), introducing the industry’s first “Physical AI” autonomous finishing fleet to modernize interior commercial construction.


Solving the Skilled Labor Shortage with Physical AI

The North American construction sector faces an unprecedented skilled labor shortage. Legend Robot delivers a battle-tested solution for the high-volume needs of commercial construction. By deploying Physical AI—artificial intelligence that interacts directly with and learns from physical environments—Legend Robot reduces labor reliance while enhancing safety in “dull, dirty, and dangerous” workspaces.

6.2m “Spray-While-Moving” Technology: Defining Mobile Continuous Operations

Legend Robot is launching two flagship models optimized for North American commercial sites: the 6.2m Latex Painting Robot and the 6.2m Putty Spraying (Skim Coat) Robot.

Unlike traditional static robots, these units feature 3rd-Generation Mobile Continuous Spraying Technology. Powered by proprietary Physical AI + Adaptive Robotics, the fleet uses 3D real-time sensing and dynamic path planning, allowing for:

  • Mobile Continuous Spraying: Non-stop motion while spraying for seamless coverage of high ceilings and expansive commercial facades.
  • Precision Finishing: “One-Pass” coverage on complex curvatures without manual rework.
  • Economic Performance: A 50% efficiency increase, translating to significant ROI and a verified reduction in construction costs by over 60%.

A New Standard for Smart Construction: A Unified Robotic Ecosystem


“We are bringing a solution that bridges the gap between robotic innovation and on-site execution,” says Jason Liang ,Marketing Director. “Legend Robot is no longer just about spraying; we are building a comprehensive smart construction ecosystem.”

Legend Robot’s updated product roadmap for 2026 sets a new industry standard by integrating:

Versatile Spraying Fleet for Commercial & Residential Projects: 

Including 6.2m models for high-volume commercial construction and specialized units for precise residential finishes.

High-Precision Tile Laying Robots:  Utilizing LiDAR technology for perfect alignment and navigation across general construction environments.

Heavy-Duty Floor Grinding Robots:  Providing consistent surface preparation with minimal human oversight.

By combining the precision of Physical AI with the ruggedness needed for diverse construction scenarios, Legend Robot offers general contractors a scalable way to stabilize project timelines and ensure consistent quality.

See the future of “Physical AI” in action at booth N12934.

Multiplier Launches Locals and Partner Perks to Strengthen the Global Employment Ecosystem

New community and partner benefits initiatives support companies scaling across borders

NEW YORK, Feb. 24, 2026 /PRNewswire/ — Multiplier, a leading global employment platform, recently announced the launch of two landmark initiatives: Multiplier Locals, a first-of-its-kind global community designed to connect customers, partners, and operators building distributed teams, and the Multiplier Partner Perks Program, a curated marketplace offering exclusive pricing and benefits across best-in-class tools. Together, these initiatives mark a significant step forward in Multiplier’s continued investment in strengthening the global employment ecosystem by expanding the company’s role beyond infrastructure to actively foster the relationships, knowledge, and operational support companies need to scale internationally with confidence.

A Dual Approach to Global Scaling

Multiplier Locals brings together a digital Community Hub, in person City Editions, and an Advocates program into one unified experience designed to connect customers and partners. Built on the belief that global success is shaped by local insight, the initiative enables HR leaders, founders, and operators to exchange practical knowledge and real world lessons from managing distributed teams. Members can access peer insights online, while City Editions extend these conversations offline through curated gatherings in markets including Singapore, London, and New York.

To turn that support into tangible value, the Partner Perks Program is designed to bring additional value specifically to Multiplier customers. The program provides access to best in class tools across HR, finance, legal, tech infrastructure, and business operations, featuring leading companies such as Notion, Ramp, HubSpot, and Intercom at preferred pricing. By integrating these curated partnerships into its ecosystem, Multiplier helps growing teams access essential solutions in one place as they expand globally.

Leadership Perspectives

“Companies today are building teams wherever the best talent lives,” said Sagar Khatri, Founder and CEO of Multiplier. “That shift brings opportunity, but it also brings complexity. We see our role expanding beyond infrastructure to building the support system around global hiring so companies can scale smarter and faster.”

“Global expansion doesn’t happen in isolation. It’s driven by shared knowledge, trusted relationships, and the right support,” said Kate Walsh, Chief Customer Officer at Multiplier. “With the launch of Multiplier Locals and our Partner Perks Program, we’re bringing this to life for the first time by creating spaces where founders, operators, and global hiring leaders can connect, learn from peers, and access meaningful benefits that help them scale globally with confidence.”

“Global employment has evolved beyond software into a dynamic ecosystem,” said Monish Munshi, Chief Marketing Officer at Multiplier. “By integrating Locals and Partner Perks, we’re bringing together community, strategic partners, and our platform into one cohesive experience that gives companies a clear competitive edge in the global talent market.”

Availability and Registration

Multiplier Locals and the Partner Perks Program are now available globally. Registrations are open for the first Multiplier Locals City Edition in Singapore on March 19, where attendees will discover how Multiplier is refining its global human platform to address the nuanced compliance needs of the APAC region. To learn more about the community, visit usemultiplier.com/multiplier-locals-advocacy, and for customers looking to access exclusive benefits, visit the Partner Perks Marketplace at usemultiplier.com/perks.

About Multiplier

Multiplier is precision-built for hiring, managing and paying global teams in 150+ countries. Founded in 2020, Multiplier’s world-class EOR, COR, Global Payroll and HRIS are all compliant by design, making it possible for businesses to expand with total peace of mind. We combine our vast network of owned entities with human-first support and cutting-edge technology to bring you the leading Global Teams Platform, defining the future of work.

Telin Partners with IPification to Launch Telin Mobile Network Verification – Revolutionizing Digital Identity at the Network Level

JAKARTA, Indonesia, Feb. 24, 2026 /PRNewswire/ — PT Telekomunikasi Indonesia International (Telin), a leading global digital connectivity and infrastructure provider, announced a strategic partnership with IPification to launch and commercialize Telin Mobile Network Verification (MNV), a network-level digital identity solution designed to deliver seamless, secure, and instant user authentication—without the need for OTPs or additional applications.

Telin Partners with IPification to Launch Telin Mobile Network Verification – Revolutionizing Digital Identity at the Network Level
Telin Partners with IPification to Launch Telin Mobile Network Verification – Revolutionizing Digital Identity at the Network Level

Fresh from a successful commercial launch with Telkomsel in Indonesia, Telin’s MNV is battle-tested and is available across more than 40 mobile networks worldwide. By blending Telin’s unmatched global network reach and operator relationships with IPification’s pioneering mobile identity technology, businesses can now silently authenticate with a single user tap consenting to the use of the network Data

Turning Networks into Trusted Identity Engines

In today’s fast-moving digital world of finance, e-commerce, gaming, OTT platforms, and public services, old-school SMS OTPs are pressured by phishing scams, SIM swaps, and bot attacks. Telin MNV redefines authentication by anchoring it directly to the network’s inherent trustworthiness. This delivers effortless, secure verification natively integrated into the infrastructure users engage with daily.

Digital identity works best when it’s built into the infrastructure users already rely on,” said Stefan Kostic, CEO of IPification. “Together with Telin, we’re enabling authentication that happens at the network level—removing unnecessary friction while giving enterprises a more secure and reliable way to verify users.

Real Results That Matter

Working silently behind the scenes, Telin MNV transforms customer journeys and business operations alike. Enterprises will enjoy instant and OTP-free authentication that delights users, protection against phishing and account takeovers, and lower costs from fewer failed attempts. Mobile operators gain a new revenue stream, turning network intelligence into high-value API services that scale effortlessly to meet massive demand.

Ready for the Biggest Stages

The solution shines for real-world mobile scenarios. “We are excited to complement our Telco APIs signals with TS.43, where Android subscribers on Wi-Fi can now be authenticated without having their mobile data turned on,” said John Tolton, SVP Messaging Mobile Identity & Voice at Telin. “This is an important development for the OTT developer community and mobile network operators, as it enhances authentication options while complementing existing SMS-based authentication revenue.

This partnership is a bold step toward making mobile networks the heart of digital trust, security, and opportunity worldwide, building directly on the Network API advancements as a continuation in Telin’s previous collaboration announcement.

About Telin

Founded in 2007, Telin is a leading global digital enabler delivering premium international mobility, connectivity and tailored solutions for wholesale, enterprise, digital, and retail customers. Telin supports its customers through global offices in Indonesia, Singapore, Hong Kong SAR, Australia, Malaysia, Taiwan region, the United States, Timor Leste, the United Arab Emirates, and Myanmar, with representatives in the United Kingdom, the Philippines, India, Vietnam, and Canada.

Telin infrastructure spans over 306,376 kilometers of submarine cable systems across 27 global networks, backed by 162 Points of Presence in 35 countries and regions, and more than 19 Tier II to Tier IV data centers in strategic locations including Singapore, Hong Kong SAR, Timor Leste, and Indonesia.

Telin is dedicated to changing the way you connect and drive digital transformation worldwide.

For more information, visit www.telin.net

Media Contact:

Pri Handoko – VP Corporate Affairs, Email: corcomm@telin.net | Phone: +62811 8400 999

About IPification

IPification is building the backbone of mobile authentication of today and tomorrow. By verifying the phone number, SIM card, and device via IP address, IPification patented technology is enabling secure, passwordless, zero-tap compatible mobile user authentication, registration, transaction approval, and fraud prevention solutions for any mobile application. Readily available across numerous countries and regions, IPification is trusted by the leading telecom, technology, payment, and OTT companies.

For more information, please visit www.ipification.com

Media Inquiry

IPification,
Alexandra Kalinina
alexandra.kalinina@ipification.com

Cellebrite Announces Participation in the Morgan Stanley Technology, Media & Telecom Conference

TYSONS CORNER, Va. and PETAH TIKVA, Israel, Feb. 24, 2026 /PRNewswire/ — Cellebrite (NASDAQ: CLBT), a global leader in AI-powered Digital Investigative and Intelligence solutions for the public and private sectors, today announced the Company will participate in the upcoming Morgan Stanley Technology, Media & Telecom Conference. Relevant details include:

 

Date:

March 3, 2026

Conference:

Morgan Stanley Technology, Media & Telecom Conference

Presentation Time:

10:45 a.m. ET

Format

Fireside Chat

Event URL:

https://investors.cellebrite.com/events/event-details/morgan-stanley-technology-media-telecom-conference   

Cellebrite Executives:     

 

David Barter, chief financial officer

Andrew Kramer, vice president, investor relations

About Cellebrite
Cellebrite’s (Nasdaq: CLBT) mission is to protect communities, nations and businesses as a global leader in digital investigative and intelligence solutions. More than 7,000 global law enforcement agencies, defense and intelligence organizations and enterprises trust Cellebrite’s AI-powered software portfolio to make forensically sound digital data more accessible and actionable. Cellebrite technology allows customers to accelerate more than 1.5 million legally sanctioned investigations annually, enhance sovereign security, elevate operational efficacy and efficiency and enable advanced mobile research and application security. Available via cloud, on-premises and hybrid deployments, Cellebrite’s technology enables its customers around the globe to advance their missions, elevate public safety and safeguard data privacy. To learn more, visit us at www.cellebrite.com

Investor Relations
Andrew Kramer
Vice President, Investor Relations
investors@cellebrite.com
+1 973.206.7760

Media
Victor Cooper
Sr. Director of Corporate Communications + Content Operations
Victor.cooper@cellebrite.com
+1 404.804.5910